JAK2 and prostate cancer: Emerging studies revealed that PTEN loss in prostate cancer resulted in an immunosuppressive tumor microenvironment through the activation of the Janus kinase 2 (JAK2)–signal transducer and activator of transcription 3 (STAT3) pathway and the subsequent secretion of immunosuppressive chemokines [38].